<DOC>
	<DOCNO>NCT00516698</DOCNO>
	<brief_summary>RATIONALE : Studying change breast density blood hormone level woman receive anastrozole exemestane breast cancer may help doctor learn long-term effect treatment may help study breast cancer future . PURPOSE : This clinical trial study change breast density blood hormone level postmenopausal woman receive anastrozole exemestane breast cancer .</brief_summary>
	<brief_title>Changes Breast Density Blood Hormone Levels Postmenopausal Women Receiving Anastrozole Exemestane Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess change percent breast density ( response 1 year aromatase inhibitor therapy ) level prior initiation treatment . - To assess change dense area ( response 1 year aromatase inhibitor therapy ) level prior initiation treatment . - To examine whether change percent breast density ( response 1 year aromatase inhibitor therapy ) pre-treatment level correlate change plasma hormone level ( estrone , estrone-sulfate , estradiol , SHBG ) drug level ( anastrozole exemestane ) time period . - To examine whether change dense area ( response 1 year aromatase inhibitor therapy ) pre-treatment mammogram correlate change plasma hormone level ( estrone , estrone-sulfate , estradiol , SHBG ) drug level ( anastrozole exemestane ) time period . - To assess whether woman high pre-treatment percent density ( upper tertile ) experience great decrease percent breast density 1 year aromatase inhibitor therapy woman low pre-treatment percent density ( low tertile ) . - To assess whether woman high pre-treatment dense area ( upper tertile ) experience great decrease dense area 1 year aromatase inhibitor therapy woman low pre-treatment dense area ( low tertile ) . - To examine association haplotype-tagged single nucleotide polymorphism gene aromatase pathway identify Mayo Clinic Indiana University Pharmacogenomics Research Network Projects , change percent area density , plasma hormone level , drug level 1 year aromatase inhibitor therapy . OUTLINE : This multicenter study . Patients undergo blood sample collection baseline 1 year initiation aromatase inhibitor therapy ( anastrozole exemestane ) . Samples analyze estrogen testosterone level additional hormone level growth factor previously link breast density could alter aromatase inhibitor use ( i.e. , sex hormone-binding globulin [ SHBG ] , DHEA , DHEA sulfate , progesterone , prolactin , insulin-like growth factor-1 [ IGF-1 ] , insulin-like growth factor bind protein 3 [ IGF BP3 ] ) . Samples also analyze anastrozole exemestane level HPLC . Pharmacogenetic study also perform . Haplotype-tagged single nucleotide polymorphism gene aromatase pathway examine . Patients also undergo mammogram baseline ( ≤ 6 month prior study registration ) 1 year initiation aromatase inhibitor therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Must histologically confirm invasive breast cancer , define follow TNM stag criterion : pT1 , pT2 , pT3 pNx , pN0 , pN1 , pN2 , pN3* Patients positive sentinel node biopsy ( pN1 ) must subsequent axillary dissection eligible Patients negative sentinel node biopsy ( pN0 ) require axillary surgery study eligibility M0 , accord follow radiologic study : Bone scan ( required alkaline phosphatase &gt; 2 x institutional upper limit normal [ ULN ] and/or symptom metastatic disease ) A confirmatory xray image study , CT scan MRI , require result bone scan questionable Abdominal ultrasound CT scan abdomen ( require AST/ALT alkaline phosphatase &gt; 2 x ULN unless elevation bone fraction ) Chest xray NOTE : *Only sole basis classification presence 10 involved axillary node Completely resect disease Surgical margin must clear invasive carcinoma ductal carcinoma situ lobular carcinoma situ Must one intact , noncancerous breast history previous breast surgery breast ( breast biopsy ) Mammogram intact , noncancerous breast require ≤ 6 month prior study registration ( craniocaudal [ top ] mediolateral oblique view [ side view ] must available ) Must register study ≥ 3 week ≤ 3 month completion chemotherapy OR primary surgery* Adjuvant chemotherapy radiation therapy prescribe local institution allow provided patient register study hormonal treatment begin soon patient sufficiently recover chemotherapy NOTE : *Primary surgery define last surgical procedure remove invasive situ disease Planning receive anastrozole exemestane ≥ 1 year treatment breast cancer Hormone receptor status : Estrogen receptor and/or progesterone receptorpositive ( defined tumor receptor content &gt; 10 fmol/mg protein OR receptorpositive immunohistochemistry [ ERICA PgRICA ] ) PATIENT CHARACTERISTICS : Inclusion criterion : Female Postmenopausal , define one following : Age &gt; 60 year Age 4559 year spontaneous cessation menses &gt; 12 month prior chemotherapy ( chemotherapy give , prior study registration ) Age 4559 year cessation menses duration &lt; 12 month secondary hysterectomy AND FSH level postmenopausal range ( ≥ 34.4 IU/L , institutional range available ) prior chemotherapy ( chemotherapy give , prior study registration ) Age 4559 year FSH level postmenopausal range accord institutional laboratory standard ( &gt; 34.4 IU/L , institutional range available ) prior chemotherapy ( chemotherapy give , prior study registration ) Bilateral oophorectomy ECOG performance status 0 , 1 , 2 Life expectancy ≥ 5 year Exclusion criterion : History ( nonbreast ) malignancy , except adequately treat nonmelanoma skin cancer , curatively treated situ cancer cervix , curatively treat solid tumor evidence disease &gt; 5 year Any coexist medical psychiatric condition likely interfere study procedure and/or result PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics Exclusion criterion : Hormone replacement therapy , oral contraceptive , tamoxifen , raloxifene , selective estrogenreceptor modulators , gonadotropin releasinghormone analogue ≤ 6 month prior preregistration mammogram Prior treatment aromatase inhibitor ( e.g. , anastrozole , exemestane , letrozole ) Planned surgery ( core needle biopsy ) intact noncancerous breast ( e.g. , preventive/prophylactic mastectomy )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>